Form D · Biotechnology

Veralox Therapeutics Inc.

Frederick, MD · CIK 0001777474

Offering snapshot reported Jun 21, 2023 · SEC filing

Reported sold
$24M
Offering amount: $25M
Investors reported
14
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 1, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 21, 2023Initial$24,013,521No comparison14SEC filing
Jul 7, 2021Initial$14,437,500No comparisonNot reportedSEC filing
May 22, 2019Initial$1,460,000No comparison6SEC filing

Offering details

Securities
Equity, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-484758
Offer and sale of shares of preferred stock and the underlying shares of common stock issuable upon conversion thereof.

Source: Form D, filed Jun 21, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jonathan Behr Director
Matthew Boxer Director, Executive
Katie Ellias Director
Christopher Gagliardi Director
Megan Krench Director
David Maloney Director, Executive
Alex Martin Director
Jonathan Mow Director, Executive
Benjamin Scruggs Director
Jamie Stiff Director
Jeffrey W. Strovel Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
4539 Metropolitan Court
Frederick, MD, 21704